A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis.
Phase of Trial: Phase III
Latest Information Update: 07 May 2018
At a glance
- Drugs NB 001 (Primary)
- Indications Herpes labialis
- Focus Registrational; Therapeutic Use
- Acronyms SHaRCS
- Sponsors BlueWillow Biologics
- 07 May 2018 According to a BlueWillow Biologics media release, NanoBio Corporation has changed its name to BlueWillow Biologics.
- 23 Jan 2012 Actual patient number (907) added as reported by ClinicalTrials.gov.
- 23 Jan 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.